Rationale and Design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk (FOURIER) Trial
Conclusions FOURIER will determine whether the addition of evolocumab to statin therapy reduces cardiovascular morbidity and mortality in patients with vascular disease.
Source: American Heart Journal - Category: Cardiology Source Type: research
More News: Cardiology | Cardiovascular | Cholesterol | Heart | Ischemic Stroke | Peripheral Vascular Disease (PVD) | Statin Therapy | Stroke | Study